

Drug Class: Growth Hormone Releasing Hormone (GHRH) Analog
Active Substance: Tesamorelin
Strength: 5 mg/vial
Form: Lyophilized Powder
Amount: 2 mL Vial
Active Life: Approx. 2–3 hours
Average Dose: 1 mg daily (subcutaneous) in research
Liver Toxicity: None
Aromatization Rate: None
Anabolic Rate: Indirect via GH/IGF-1 axis
Androgenic Rate: None
Manufacturer: Peptide Hubs
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), designed to stimulate natural GH production through the pituitary. Manufactured by Peptide Hubs, this research-grade peptide is delivered as a 5 mg lyophilized powder in a 2 mL vial, ideal for clinical research into visceral fat reduction, lipodystrophy, and metabolic improvements.
Tesamorelin mimics the function of GHRH, stimulating the anterior pituitary to secrete more growth hormone. Unlike other GH secretagogues, Tesamorelin is FDA-approved for treating HIV-associated lipodystrophy due to its ability to reduce visceral adipose tissue. Research from NIH-backed studies also shows promising effects on insulin sensitivity and lipid profiles.
This peptide is particularly valued for its selectivity and safety profile. It does not induce prolactin or cortisol spikes and primarily targets GH secretion. Researchers studying aging, cognitive decline, and visceral fat accumulation have shown increasing interest in GHRH analogs like Tesamorelin. Some stack it with CJC-1295 DAC or Ipamorelin for enhanced outcomes.
In laboratory settings, typical dosing ranges from 1–2 mg/day subcutaneously, depending on research objectives. Tesamorelin exhibits a strong pulse in GH secretion with minimal receptor desensitization. Studies suggest it remains effective even with prolonged use. Learn more on our BPC-157 5 mg and Thymalin 10 mg pages for peptide stacking strategies.
Those conducting research in the US trust Peptide Hubs' Tesamorelin formulation for its purity, stability, and accurate dosing. The peptide is manufactured in GMP-compliant facilities and third-party tested to ensure results you can replicate with confidence.
Yes, it is FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. However, this product is sold strictly for research purposes.
It stimulates the pituitary gland to release endogenous growth hormone, mimicking the action of natural GHRH.
Yes, it's widely studied for its ability to reduce visceral adipose tissue and support metabolic regulation in fat loss research models.
Store the vial in a refrigerator at 2–8°C. After reconstitution with bacteriostatic water, use within 20–30 days.
Please log in to write Tesamorelin 5 mg review.
Drug Class: GHRH Analog
Active Substance: Tesamorelin
Strength: 5 mg/vial
Form: Lyophilized Powder
Amount: 2 mL Vial
Active Life: ~2 hours (biological activity longer via IGF-1 axis)
Average Dose: 1 mg/day subcutaneously
Liver Toxicity: None
Aromatization Rate: None
Anabolic Rate: Mild via GH pathway
Androgenic Rate: None
Manufacturer: Dragon Pharma
Drug Class: Peptide Hormone (Gonadotropin)
Active Substance: Human Chorionic Gonadotropin (HCG)
Strength: 2500 IU/vial
Form: Lyophilized Powder
Amount: 2 mL Vial
Active Life: 64–72 hours
Average Dose: 250–1000 IU 2–3x/week (PCT); 500–2000 IU/week (on-cycle support)
Liver Toxicity: None
Aromatization Rate: Indirectly increases estrogen via testosterone conversion
Anabolic Rate: None (supports natural testosterone production)
Androgenic Rate: Low (via LH stimulation)
Manufacturer: Dragon Pharma
Laboratory Test: View Result